Acute Myeloid Leukemia Mutation Panel by Next Generation Sequencing
Use to assess for single gene mutations, including substitutions and smaller insertions and deletions, that may have prognostic and/or therapeutic significance in acute myeloid leukemia (AML).
Massively Parallel Sequencing
New York DOH Approval Status
Lavender (EDTA), Green (sodium heparin) Bone Marrow (EDTA) or Bone Marrow (sodium heparin), Fresh-frozen tissue.
Whole Blood and Bone Marrow: Transport 3 mL. (Min: 1.5 mL)
Fresh-frozen Tissue: Transport 5 mg fresh-frozen tissue.
Separate specimens must be submitted when multiple tests are ordered
Whole Blood or Bone Marrow: Refrigerated.
Fresh-frozen Tissue: Frozen.
Serum, plasma, grossly hemolyzed specimens, buccal brush or swab, FFPE tissue
Whole Blood or Bone Marrow: Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
Fresh-frozen Tissue: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
Genes tested: ANKRD26, ASXL1, CEBPA, DDX41, DNMT3A, ETV6, FLT3, GATA2, IDH1, IDH2, KIT, KRAS, NPM1*, NRAS, RUNX1, TP53, WT1
* One or more exons are not covered by sequencing for the indicated gene; see Additional Technical Information.
|Component Test Code*||Component Chart Name||LOINC|
|3002715||Acute Myeloid Leukemia Specimen|
|3002716||Acute Myeloid Leukemia Interp|
|3002718||EER, AML Panel by NGS||11502-2|